Proteopedia

Biktarvy

Bictegravir/emtricitabine/tenofovir alafenamide, sold under the brand name Biktarvy, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS. One tablet, taken orally once daily, contains 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide.[1] It was approved for use in the United States in February 2018,[2][3] and for use in the European Union in June 2018.[4]

Bictegravir (integrase inhibitor):

Emtricitabine (nucleotide reverse transcriptase inhibitor):

  • .
  • at reverse transcriptase (2no6). Water molecules are shown as red spheres.

Tenofovir alafenamide (nucleotide reverse transcriptase inhibitor):

  • .

Caption for this structure

Drag the structure with the mouse to rotate

ReferencesReferences

  1. ↑ "Biktarvy- bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate tablet". DailyMed. 8 August 2019. Retrieved 7 March 2020.
  2. ↑ "Drug Approval Package: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) Tablets". U.S. Food and Drug Administration (FDA). 19 March 2018. Retrieved 7 March 2020.
  3. ↑ "U.S. Food and Drug Administration Approves Gilead's Biktarvy (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection" (Press release). Gilead. 7 February 2018.
  4. ↑ "Biktarvy EPAR". European Medicines Agency (EMA). 21 January 2020. Retrieved 7 March 2020.

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky
Retrieved from "https://proteopedia.openfox.io/wiki/index.php?title=Biktarvy&oldid=3847265"